Evidence map›Paper›PMID 40316742›Full record

ArticleOncogene2025

Correction: Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.

M Ceccon, M E Boggio Merlo, L Mologni, T Poggio, L M Varesio, M Menotti, S Bombelli, R Rigolio, A D Manazza, F Di Giacomo and 9 more

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

M Ceccon *Department of Health Science, University of Milano-Bicocca, Monza, Italy.
M E Boggio Merlo *Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
L MologniDepartment of Health Science, University of Milano-Bicocca, Monza, Italy.
T PoggioDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
L M VaresioDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
M MenottiDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
S BombelliDepartment of Health Science, University of Milano-Bicocca, Monza, Italy.
R RigolioSurgery and Translational Medicine Department, University of Milano-Bicocca, Monza, Italy.
A D ManazzaDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
F Di GiacomoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
C AmbrogioMolecular Oncology Program, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain.
G GiudiciTettamanti Research Centre, Pediatric Clinic, University of Milano-Bicocca, Monza, Italy.
C CasatiMetaSystems s.l.r., Milano, Italy.
C MastiniDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
M CompagnoDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
S D TurnerDivision of Molecular Histopathology, Addenbrooke's Hospital Cambridge, Cambridge, UK.
C Gambacorti-PasseriniDepartment of Health Science, University of Milano-Bicocca, Monza, Italy. carlo.gambacorti@unimib.it.
R ChiarleDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy. roberto.chiarle@childrens.harvard.edu.
C VoenaDepartment of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40316742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.